79 related articles for article (PubMed ID: 21926939)
1. Longitudinal anatomical response of retinal-choroidal anastomosis to anti-vascular endothelial growth factor therapy.
Querques G; Rousseau A; Forte R; Scemama C; Caillaux V; Querques L; Souied EH
Retina; 2012 Mar; 32(3):458-67. PubMed ID: 21926939
[TBL] [Abstract][Full Text] [Related]
2. Angiographic analysis of retinal-choroidal anastomosis by confocal scanning laser ophthalmoscopy technology and corresponding (eye-tracked) spectral-domain optical coherence tomography.
Querques G; Atmani K; Berboucha E; Martinelli D; Coscas G; Soubrane G; Souied EH
Retina; 2010 Feb; 30(2):222-34. PubMed ID: 19952987
[TBL] [Abstract][Full Text] [Related]
3. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function.
Kiss CG; Geitzenauer W; Simader C; Gregori G; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2376-83. PubMed ID: 19136707
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
7. Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab.
Querques G; Querques L; Rafaeli O; Canoui-Poitrine F; Bandello F; Souied EH
Invest Ophthalmol Vis Sci; 2011 Sep; 52(9):7012-8. PubMed ID: 21885622
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
9. A new grading system for retinal pigment epithelial tears.
Sarraf D; Reddy S; Chiang A; Yu F; Jain A
Retina; 2010; 30(7):1039-45. PubMed ID: 20458264
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography.
Nagiel A; Freund KB; Spaide RF; Munch IC; Larsen M; Sarraf D
Am J Ophthalmol; 2013 Nov; 156(5):981-988.e2. PubMed ID: 23972309
[TBL] [Abstract][Full Text] [Related]
11. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy.
Golbaz I; Ahlers C; Stock G; Schütze C; Schriefl S; Schlanitz F; Simader C; Prünte C; Schmidt-Erfurth UM
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1599-605. PubMed ID: 21051733
[TBL] [Abstract][Full Text] [Related]
12. Multimodal imaging of early stage 1 type 3 neovascularization with simultaneous eye-tracked spectral-domain optical coherence tomography and high-speed real-time angiography.
Querques G; Souied EH; Freund KB
Retina; 2013 Oct; 33(9):1881-7. PubMed ID: 23644560
[TBL] [Abstract][Full Text] [Related]
13. Additional anti-vascular endothelial growth factor therapy for eyes with a retinal pigment epithelial tear after the initial therapy.
Asao K; Gomi F; Sawa M; Nishida K
Retina; 2014 Mar; 34(3):512-8. PubMed ID: 23945637
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.
Saito M; Iida T; Kano M
Retina; 2011 Sep; 31(8):1589-97. PubMed ID: 21654347
[TBL] [Abstract][Full Text] [Related]
15. Anatomical and visual outcomes of ranibizumab injections in retinal pigment epithelium tears.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Sari ES
Arq Bras Oftalmol; 2015; 78(3):168-72. PubMed ID: 26222106
[TBL] [Abstract][Full Text] [Related]
16. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
Zweifel SA; Saroj N; Shapiro H; Freund KB
Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
[TBL] [Abstract][Full Text] [Related]
17. Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
Young M; Chui L; Fallah N; Or C; Merkur AB; Kirker AW; Albiani DA; Forooghian F
Retina; 2014 Jul; 34(7):1308-15. PubMed ID: 24451923
[TBL] [Abstract][Full Text] [Related]
18. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
19. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
Song MH; Ryu HW; Roh YJ
Ophthalmologica; 2011; 226(3):119-26. PubMed ID: 21757883
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation.
Cho HJ; Yoo SG; Kim HS; Kim JH; Kim CG; Lee TG; Kim JW
Am J Ophthalmol; 2015 Feb; 159(2):285-92.e1. PubMed ID: 25447115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
